Nautilus Biotechnology Reports Third Quarter 2025 Financial Results
Nautilus Biotechnology (NASDAQ: NAUT) reported third quarter 2025 results for the period ended September 30, 2025. Key operational milestones include continued processing of Tau proteoform samples with collaborators and progress on a broadscale assay format intended to support a commercial launch in late 2026. The company expects an early access program for Tau proteoforms in the first half of 2026 and plans to share collaborator data at the upcoming World HUPO conference.
Financial highlights: Operating expenses were $15.5 million in Q3 2025, down 19% year-over-year; net loss was $13.6 million versus $16.4 million a year earlier; and cash, cash equivalents, and investments totaled $168.5 million as of September 30, 2025. A conference call and webcast were scheduled for October 28, 2025 at 5:30 AM PT.
Nautilus Biotechnology (NASDAQ: NAUT) ha riportato risultati del terzo trimestre 2025 per il periodo terminato il 30 settembre 2025. Le principali tappe operative includono il continuo processamento di campioni di tau proteoforma con collaboratori e progressi su una formato di test su larga scala volto a supportare un lancio commerciale nel fine del 2026. L'azienda prevede un programma di accesso anticipato per le proteoforme Tau nella prima metà del 2026 e intende condividere i dati dei collaboratori alla prossima conferenza World HUPO.
Aspetti finanziari salienti: spese operative ammontavano a 15,5 milioni di dollari nel Q3 2025, in calo del 19% rispetto all'anno precedente; perdita netta era di 13,6 milioni di dollari contro 16,4 milioni di dollari un anno prima; e liquidi, equivalenti di liquidità e investimenti ammontavano a 168,5 milioni di dollari al 30 settembre 2025. Una conference call e webcast erano programmati per il 28 ottobre 2025 alle 5:30 AM PT.
Nautilus Biotechnology (NASDAQ: NAUT) informó los resultados del tercer trimestre de 2025 para el período finalizado el 30 de septiembre de 2025. Los hitos operativos clave incluyen el procesamiento continuo de muestras de tau proteoforma con colaboradores y avances en un formato de ensayo a gran escala destinado a respaldar un lanzamiento comercial para finales de 2026. La empresa espera un programa de acceso anticipado para las proteoformas Tau en la primera mitad de 2026 y planea compartir datos de colaboradores en la próxima conferencia World HUPO.
Aspectos financieros clave: gastos de operación fueron de 15,5 millones de dólares en el Q3 2025, una disminución del 19% interanual; pérdida neta fue de 13,6 millones de dólares frente a 16,4 millones de dólares un año antes; y efectivo, equivalentes de efectivo e inversiones totalizaron 168,5 millones de dólares al 30 de septiembre de 2025. Una llamada de conferencia y webinario estaban programados para el 28 de octubre de 2025 a las 5:30 a.m. PT.
네이틸러스 생명공학(NASDAQ: NAUT)은 2025년 9월 30일 종료된 2025년 3분기 실적을 발표했습니다. 주요 운영 이정표로는 협력자들과 함께 tau 프로테오폼 샘플의 지속적인 처리와 광범위한 검사 형식에 대한 진전이 포함되며, 2026년 말 상업 출시를 지원하기 위한 것입니다. 회사는 tau 프로테오폼에 대한 조기 접근 프로그램을 2026년 상반기에 시행할 것으로 예상하며, 협력자 데이터는 다가오는 World HUPO 학술대회에서 공유할 계획입니다.
재무 하이라이트: 영업비용은 2025년 3분기에 1550만 달러로 전년 동기 대비 19% 감소; 순손실은 1360만 달러로 작년 동기의 1640만 달러 대비 감소; 현금 및 현금성자산 및 투자은 2025년 9월 30일 기준 1억 6850만 달러였습니다. 2025년 10월 28일 오전 5시 30분 PT에 콘퍼런스 콜과 웹시트가 예정되어 있었습니다.
Nautilus Biotechnology (NASDAQ: NAUT) a publié les résultats du troisième trimestre 2025 pour la période se terminant le 30 septembre 2025. Les jalons opérationnels clés incluent le traitement continu d'échantillons de tau protéiforme avec des partenaires et des avancées dans un format de test à grande échelle destiné à soutenir un lancement commercial à fin 2026. L'entreprise prévoit un programme d'accès anticipé pour les protéiformes Tau au cours de la première moitié de 2026 et prévoit de partager les données des partenaires lors de la prochaine conférence World HUPO.
Points financiers clés : Dépenses d'exploitation se sont élevées à 15,5 millions de dollars au T3 2025, soit une baisse de 19 % d'une année sur l'autre; perte nette de 13,6 millions de dollars contre 16,4 millions de dollars l'année précédente; et trésorerie, équivalents de trésorerie et investissements s'élevant à 168,5 millions de dollars au 30 septembre 2025. Une conférence téléphonique et une webdiffusion étaient prévues pour le 28 octobre 2025 à 5h30 PT.
Nautilus Biotechnology (NASDAQ: NAUT) berichtete die Ergebnisse des dritten Quartals 2025 für den Zeitraum bis zum 30. September 2025. Zu den wichtigsten operativen Meilensteinen gehören die fortgesetzte Verarbeitung von Tau-Proteoformen-Proben mit Kooperationspartnern und Fortschritte bei einem Breit-Skalentestformat, das einen kommerziellen Markteintritt Ende 2026 unterstützen soll. Das Unternehmen erwartet ein Early-Access-Programm für Tau-Proteoformen in der ersten Hälfte des Jahres 2026 und plant, Kooperationsdaten auf der kommenden World HUPO-Konferenz zu teilen.
Finanzielle Highlights: Betriebskosten beliefen sich im Q3 2025 auf 15,5 Mio. USD, ein Rückgang von 19% gegenüber dem Vorjahr; Nettoverlust betrug 13,6 Mio. USD gegenüber 16,4 Mio. USD im Vorjahr; und Kassenbestand, liquide Mittel und Investitionen beliefen sich zum 30. September 2025 auf 168,5 Mio. USD. Eine Telefonkonferenz und Webcast waren für den 28. Oktober 2025 um 05:30 Uhr PT vorgesehen.
Nautilus Biotechnology (بورصة ناسداك: NAUT) أعلنت نتائج الربع الثالث من عام 2025 للفترة المنتهية في 30 سبتمبر 2025. تشمل المعالم التشغيلية الرئيسية الاستمرار في معالجة عينات طور-بروتين تاو بالتعاون مع شركاء وتقدم في صيغة اختبار واسعة النطاق تهدف لدعم الإطلاق التجاري في أواخر 2026. تتوقع الشركة برنامج وصول مبكر لطور-بروتين تاو في النصف الأول من 2026 وتخطط لمشاركة بيانات الشركاء في المؤتمر World HUPO القادم.
أبرز النقاط المالية: النفقات التشغيلية كانت 15.5 مليون دولار في الربع الثالث 2025، منخفضة 19% مقارنة بالعام السابق؛ وبلغت الخسارة الصافية 13.6 مليون دولار مقابل 16.4 مليون دولار قبل عام؛ وتبلغ النقد والنقد المكافئ والاستثمار الإجمالي 168.5 مليون دولار كما في 30 سبتمبر 2025. وكان هناك مكالمة هاتفية وبث إلكتروني مخطط لهما في 28 أكتوبر 2025 الساعة 5:30 صباحاً بتوقيت الساحل الشرقي.
Nautilus Biotechnology (NASDAQ: NAUT) 报告了截至2025年9月30日的2025年第三季度业绩。 主要运营里程碑包括与合作伙伴持续处理 tau 蛋白结构变体样本，以及推进一个大规模分析格式，旨在支持在2026年末的商业发布。公司预计在2026年上半年推出 Tau 蛋白结构变体的提前获取计划，并计划在即将举行的 World HUPO 会议上共享合作伙伴数据。
财务要点：运营费用在2025年第三季度为1505万美元，同比下降19%；净亏损为1360万美元，较去年同期的1640万美元有所下降；现金及现金等价物和投资截至2025年9月30日合计1.685亿美元。计划于2025年10月28日UTC凌晨5:30举行电话会议和网络直播。
- Operating expenses down 19% year-over-year in Q3 2025
- Net loss reduced to $13.6M from $16.4M year-over-year (~17% decline)
- Cash and investments of $168.5M as of September 30, 2025
- Progress on Tau proteoform sample processing and publications
- Development of a broadscale assay aimed at late-2026 commercial launch
- Early access program planned for H1 2026
- Net loss of $13.6M in Q3 2025
- No product revenue reported; commercial availability not expected until late 2026
Insights
Nautilus reports lower quarterly losses, a solid cash position, and milestones toward early access in
Nautilus reduced operating expenses to
The operational story centers on two product milestones: an early access program for Tau proteoforms planned in
Watch for three concrete near-term datapoints: published Tau proteoform results at World HUPO, initiation of the early access program in
SEATTLE, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2025.
Third Quarter 2025 Business Highlights
- Continued progress was made in processing Tau proteoform samples from collaborators in support of our goals of product validation and growing our publications. We expect to share this data at the upcoming World HUPO conference.
- Further progress was made in the development of a new broadscale assay format, which is intended to support our forthcoming commercial launch in late 2026.
- We expect to launch our early access program with Tau proteoforms in the first half of 2026.
“In Q3, Nautilus maintained disciplined execution and delivered meaningful progress across our platform, strategic collaborations, and operational initiatives—all aligned with our path toward commercialization in late 2026,” said Sujal Patel, CEO of Nautilus Biotechnology. “Our near-term focus is on the successful launch of our early access program, beginning with Tau proteoforms in the first half of 2026 and expanding to broadscale capabilities later in the year. These milestones are critical steps toward enabling customers to experience the value of our technology and advancing toward full commercial availability.”
Third Quarter 2025 Financial Results
Operating expenses were
Net loss was
Cash, cash equivalents, and investments were
Webcast and Conference Call Information
Nautilus will host a conference call to discuss the third quarter 2025 financial results, business developments and outlook before market open on Tuesday, October 28, 2025, at 5:30 AM Pacific Time / 8:30 AM Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.nautilus.bio.
About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio
Special Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws. Forward-looking statements in this press release include, but are not limited to, statements regarding Nautilus’ expectations regarding the company’s business operations, financial performance and results of operations; expectations regarding operating expenses and cash runway; expectations with respect to any revenue timing or projections; expectations with respect to the development required for and the timing of the launch of Nautilus’ product platform and full commercial availability; the functionality and performance of Nautilus’ product platform, its potential impact on providing proteome or proteoform access, pharmaceutical development and drug discovery, expanding research horizons, and enabling scientific explorations and discovery; expectations regarding platform specifications required by potential customers and partners and the timeline for adoption of Nautilus’ platform by researchers; and the present and future capabilities and limitations of emerging proteomics technologies. These statements are based on numerous assumptions concerning the development of Nautilus’ products, target markets, and other current and emerging proteomics technologies, and involve substantial risks, uncertainties and other factors that may cause actual results to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that could materially affect the accuracy of Nautilus’ assumptions and its ability to achieve the forward-looking statements set forth in this press release include (without limitation) the following: Nautilus’ product platform is not yet commercially available and remains subject to significant scientific and technical development, which is inherently challenging and difficult to predict, particularly with respect to highly novel and complex products such as those being developed by Nautilus. Even if our development efforts are successful, our product platform will require substantial validation of its functionality and utility in life science research. In the course of Nautilus’ scientific and technical development and associated product validation and commercialization, we may experience material delays as a result of unanticipated events. We cannot provide any guarantee or assurance with respect to the outcome of our development, collaboration, and commercialization initiatives or with respect to their associated timelines. For a more detailed description of additional risks and uncertainties facing Nautilus and its development efforts, investors should refer to the information under the caption “Risk Factors” in our Annual Report on Form 10-K as well as in our Quarterly Report on Form 10-Q to be filed for the quarter ended September 30, 2025 and our other filings with the SEC. The forward-looking statements in this press release are as of the date of this press release. Except as otherwise required by applicable law, Nautilus disclaims any duty to update any forward-looking statements. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
Disclosure Information
Nautilus uses filings with the Securities and Exchange Commission, its website (www.nautilus.bio), press releases, public conference calls, public webcasts, and its social media accounts as means of disclosing material non-public information and for complying with Regulation FD. Therefore, Nautilus encourages investors, the media, and others interested in Nautilus to review the information it makes public in these locations, as such information could be deemed to be material information.
Media Contact
press@nautilus.bio
Investor Contact
investorrelations@nautilus.bio
Nautilus Biotechnology, Inc. Condensed Consolidated Balance Sheets As of September 30, 2025 and December 31, 2024 (Unaudited) | ||||||||
| (in thousands) | September 30, 2025 | December 31, 2024 | ||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 23,875 | $ | 27,646 | ||||
| Short-term investments | 107,552 | 102,247 | ||||||
| Prepaid expenses and other current assets | 2,898 | 2,933 | ||||||
| Total current assets | 134,325 | 132,826 | ||||||
| Property and equipment, net | 3,624 | 4,076 | ||||||
| Operating lease right-of-use assets | 24,727 | 28,256 | ||||||
| Long-term investments | 37,059 | 76,405 | ||||||
| Other long-term assets | 1,180 | 1,180 | ||||||
| Total assets | $ | 200,915 | $ | 242,743 | ||||
| Liabilities and Stockholders' Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 893 | $ | 987 | ||||
| Accrued expenses and other liabilities | 3,880 | 2,548 | ||||||
| Current portion of operating lease liabilities | 4,209 | 4,097 | ||||||
| Total current liabilities | 8,982 | 7,632 | ||||||
| Operating lease liabilities, net of current portion | 22,794 | 26,381 | ||||||
| Total liabilities | 31,776 | 34,013 | ||||||
| Stockholders' equity: | ||||||||
| Preferred stock | — | — | ||||||
| Common stock | 13 | 13 | ||||||
| Additional paid-in capital | 487,165 | 481,679 | ||||||
| Accumulated other comprehensive income | 200 | 57 | ||||||
| Accumulated deficit | (318,239 | ) | (273,019 | ) | ||||
| Total stockholders’ equity | 169,139 | 208,730 | ||||||
| Total liabilities and stockholders' equity | $ | 200,915 | $ | 242,743 | ||||
| Nautilus Biotechnology, Inc. Condensed Consolidated Statements of Operations Three and Nine Months Ended September 30, 2025 and 2024 (Unaudited) | ||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| (in thousands, except share and per share data) | 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Research and development | $ | 9,605 | $ | 12,288 | $ | 31,535 | $ | 37,654 | ||||||||
| General and administrative | 5,867 | 6,812 | 19,878 | 23,842 | ||||||||||||
| Total operating expenses | 15,472 | 19,100 | 51,413 | 61,496 | ||||||||||||
| Other income (expense): | ||||||||||||||||
| Interest income | 1,903 | 2,674 | 6,214 | 8,349 | ||||||||||||
| Other expense | (5 | ) | (20 | ) | (21 | ) | (39 | ) | ||||||||
| Total other income | $ | 1,898 | $ | 2,654 | $ | 6,193 | $ | 8,310 | ||||||||
| Net loss | $ | (13,574 | ) | $ | (16,446 | ) | $ | (45,220 | ) | $ | (53,186 | ) | ||||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.11 | ) | $ | (0.13 | ) | $ | (0.36 | ) | $ | (0.42 | ) | ||||
| Weighted-average shares used in computing net | ||||||||||||||||
| loss per share attributable to common stockholders, basic and diluted | 126,305,122 | 125,452,572 | 126,218,587 | 125,302,440 | ||||||||||||
| Nautilus Biotechnology, Inc. Condensed Consolidated Statements of Operations Three and Nine Months Ended September 30, 2025 and 2024 (Unaudited) | ||||||||
| Nine Months Ended September 30, | ||||||||
| (in thousands) | 2025 | 2024 | ||||||
| Cash flows from operating activities | ||||||||
| Net loss | $ | (45,220 | ) | $ | (53,186 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities | ||||||||
| Stock-based compensation expense | 5,373 | 9,577 | ||||||
| Amortization of operating lease right-of-use assets | 3,529 | 3,257 | ||||||
| Depreciation | 1,348 | 1,543 | ||||||
| Amortization (accretion) of premium (discount) on securities, net | (1,286 | ) | (2,176 | ) | ||||
| Changes in operating assets and liabilities: | ||||||||
| Prepaid expenses and other assets | 149 | (26 | ) | |||||
| Accounts payable | (71 | ) | (35 | ) | ||||
| Accrued expenses and other liabilities | 1,332 | (729 | ) | |||||
| Operating lease liabilities | (3,475 | ) | (3,061 | ) | ||||
| Net cash used in operating activities | (38,321 | ) | (44,836 | ) | ||||
| Cash flows from investing activities | ||||||||
| Proceeds from maturities of securities | 74,241 | 90,410 | ||||||
| Purchases of securities | (38,771 | ) | (59,398 | ) | ||||
| Purchases of property and equipment | (1,033 | ) | (1,868 | ) | ||||
| Net cash provided by investing activities | 34,437 | 29,144 | ||||||
| Cash flows from financing activities | ||||||||
| Proceeds from exercise of stock options | 26 | 415 | ||||||
| Proceeds from issuance of common stock under employee stock purchase plan | 87 | 289 | ||||||
| Net cash provided by financing activities | 113 | 704 | ||||||
| Net decrease in cash, cash equivalents and restricted cash | (3,771 | ) | (14,988 | ) | ||||
| Cash, cash equivalents and restricted cash at beginning of period | 28,648 | 20,399 | ||||||
| Cash, cash equivalents and restricted cash at end of period | $ | 24,877 | $ | 5,411 | ||||
FAQ
What were Nautilus (NAUT) Q3 2025 operating expenses and how did they change year-over-year?
How much cash did Nautilus (NAUT) have at September 30, 2025?
When does Nautilus (NAUT) expect to launch its early access program for Tau proteoforms?
What commercialization timeline did Nautilus (NAUT) provide for its broadscale assay?
Did Nautilus (NAUT) report a smaller net loss in Q3 2025 compared with a year earlier?
Where can investors access Nautilus (NAUT) Q3 2025 results and the October 28, 2025 webcast?
